Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Fig. 2

Effect of Emab on cell proliferation. Tonsillar CD10–CD27– B cells were negatively selected using magnetic bead cell enrichment and then stimulated with TLR7 agonist R848 and/or F(ab′)2 anti-human IgM with or without Emab or a human IgG control. Cells were labeled with CFSE and cultured for 3 days with different stimuli, and levels of cell proliferation were measured based on CFSE dilution. Gates depict CFSElo (proliferating) cells. a Flow cytometry data from one representative experiment. b Cumulative data from five independent experiments using CD10–CD27– enriched B cells from different donors. *p < 0.05 by two-way ANOVA analysis with Bonferroni post tests. Emab epratuzumab

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us